AmerisourceBergen Foundation donates drug disposal tools
The AmerisourceBergen Foundation has distributed nearly 55,000 drug disposal resources to communities nationwide, the charitable arm of Valley Forge, Pa.-based AmerisourceBergen said Monday. The resources, donated through the AmerisourceBergen Foundation Municipal Support Program, contain ingredients that deactivate opioids when combined with water.
The foundation’s efforts to make disposal of unused medication easier come as a recent Substance Abuse and Mental Health Services Administration Survey found that nearly 40% of people who have misused prescription pain medication obtained them from a friend or relative.
“We are encouraged by the immediate reach and impact of the grant program, and remain steadfast in our commitment to providing the communities where we live and work with the critical resources needed to help drive sustained change and combat the epidemic of opioid misuse,” said Gina Clark, AmerisourceBergen Foundation president and AmerisourceBergen executive vice president and chief communications and administration officer.
The company recently marked the introduction of the resources in the North Carolina cities of Stanley, Belmont, Rutherfordton and Shelby alongside Rep. Patrick McHenry, R.-N.C.
“The opioid epidemic is devastating families and communities all across the country, including western North Carolina,” McHenry said. “We must take action to end this crisis. Collaboration between companies like AmerisourceBergen and local communities like the town of Stanley are crucial in the fight against the opioid epidemic. I am thankful for the efforts of the AmerisourceBergen Foundation and their donation to the town of Stanley and other communities here in the Tenth District as they work to end opioid abuse.”
The AmerisourceBergen Foundation said that in the past several months, it has announced partnerships and grants aimed at providing opioid abuse, misuse and diversion prevention resources. Municipal entities and nonprofits interested in applying for resources can apply here.
Generic Alkeran launches from Fresenius Kabi
Fresenius Kabi has introduced its generic Alkeran (melphalan hydrochloride for injection). The drug is indicated as a palliative treatment for patients with multiple myeloma for whom oral therapy is not appropriate.
Fresenius Kabi’s generic Alkeran is available as a two-vial kit with one single-dose vial of the drug and one vial of sterile diluent.
Mayne Pharma adds generic Cordarone dosage strength
Mayne Pharma has launched its 200-mg generic Cordarone tablets (amiodarone). The drug is indicated to treat life-threatening recurrent ventricular arrhythmia.
The 200-mg generic Cordarone joins the 100- and 400-mg strength tablets that the Greenville, N.C.-based company had previously launched. The product had U.S. sales of roughly $22 million for the 12 months ended January 2018.
The latest launch is being manufactured at Mayne Pharma’s new manufacturing facility in Greenville that was completed recently, and which CEO Scott Richards said has potential to improve the company’s manufacturing capabilities.
“This new solid oral-dose manufacturing facility quadruples the company’s U.S. manufacturing capacity to well over 1 billion doses annually, and importantly introduces significant capacity to manufacture potent compounds and new capability to manufacture modified-release bead/pellet products,” Richards said.